Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 5Advanced Solid Tumors 5Advanced Solid Tumour 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Small Cell Lung Carcinoma 2Recurrence 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Advanced Lung Cancer 2Unresectable Locally Recurrent Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Non-small Lung Cancer 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Metastatic Solid Tumors 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Idiopathic Pulmonary Fibrosis 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Depression 1

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Injections × 30 days × Clear all
NCT07002034 2026-05-06

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Reunion Neuroscience Inc

Phase 2 Recruiting
100 enrolled

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡